Mesoblast Ltd Files 6-K Report
Ticker: MEOBF · Form: 6-K · Filed: Dec 30, 2025 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | Dec 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, foreign-private-issuer, regulatory-update
TL;DR
MESO files 6-K on 12/30/25 - likely an update for investors.
AI Summary
On December 30, 2025, Mesoblast Limited filed a new release announcement with the Australian Securities Exchange. This report is filed as a Form 6-K with the SEC, indicating it's a report from a foreign private issuer. The company is incorporated in Australia and its CEO is Silviu Itescu.
Why It Matters
This filing indicates Mesoblast Limited is providing an update to the market and regulators, which could contain significant business or financial information.
Risk Assessment
Risk Level: low — A Form 6-K is typically a routine filing for foreign private issuers to report information made public in their home country.
Key Players & Entities
- Mesoblast Limited (company) — Registrant
- Silviu Itescu (person) — Chief Executive Officer and Executive Director
- December 30, 2025 (date) — Filing date
- Australian Securities Exchange (company) — Exchange where announcement was filed
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, pursuant to the laws of their home country, or that they have filed or will file with a stock exchange on which they are traded.
When was this Form 6-K filed?
This Form 6-K was filed on December 30, 2025.
Who is the CEO of Mesoblast Limited?
Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.
Where is Mesoblast Limited incorporated?
Mesoblast Limited is incorporated in Australia.
What is the SIC code for Mesoblast Limited?
The Standard Industrial Classification (SIC) code for Mesoblast Limited is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 255 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2025-12-29 19:10:38
Filing Documents
- form6-kxpressreleasecoverf.htm (6-K) — 17KB
- exhibit991debtrefinancea.htm (EX-99.1) — 9KB
- exhibit992debtrefinancea.htm (EX-99.2) — 8KB
- exhibit991debtrefinancea001.jpg (GRAPHIC) — 273KB
- exhibit991debtrefinancea002.jpg (GRAPHIC) — 267KB
- exhibit992debtrefinancea001.jpg (GRAPHIC) — 68KB
- exhibit992debtrefinancea002.jpg (GRAPHIC) — 98KB
- exhibit992debtrefinancea003.jpg (GRAPHIC) — 113KB
- exhibit992debtrefinancea004.jpg (GRAPHIC) — 142KB
- exhibit992debtrefinancea005.jpg (GRAPHIC) — 105KB
- 0001345099-25-000113.txt ( ) — 1502KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Niva Sivakumar Niva Sivakumar Company Secretary Dated December 30, 2025 INDEX TO EXHIBITS Item 99.1 Press release of Mesoblast Ltd, dated December 30, 2025. 99.2 Appendix 3B of Mesoblast Ltd, dated December 30, 2025.